Poster Area News Today

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present three abstracts at the European Congress of Clinical Microbiology and Infectious Diseases...

Montrouge, France, November 9, 2023 DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial of Viaskin™ Peanut in Toddlers Viaskin Peanut showed...

Montrouge, France, November 9, 2023DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPE...

Montrouge, France, November 2, 2023DBV Technologies to Present New Data at ACAAI 2023New data to include late-breaking abstract detailing interim ...

Press release content from Business Wire. The AP news staff was not involved in its creation.

-- WU-NK-101 exhibited enhanced metabolic fitness and adaptability, enabling superior resilience within the immunosuppressive solid tumor microenvironment and preserved cytotoxic function ---- WU-NK-101 demonstrated robust anti-tumor activity, tumor trafficking, and penetration further augmented by monoclonal antibo...

-- WU-NK-101 exhibited enhanced metabolic fitness and adaptability, enabling superior resilience within the immunosuppressive solid tumor microenvironment and preserved cytotoxic function -- --

HMBD-001 is a proprietary anti-HER3 antibody in an ongoing Phase 1 trial targeting multiple solid tumors HMBD-001 has the potential to fully block...

/PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced...

iCRO: scientific poster presentation on Sep 10, 2022: "Challenges to Assess Bone Metastases in Blinded Independent Central Review (BICR) of Breast Cancer Trials Using RECIST 1.1" iBiopsy: